Kathy A. Mulgrew
AstraZeneca (United States) · 137 works · 2,459 citations · h-index 19
Top works
- Identification and Characterization of MEDI4736, an Antagonistic Anti–PD-L1 Monoclonal Antibody
- Adenovirus Serotype 5 Fiber Shaft Influences In Vivo Gene Transfer in Mice
- Targeting CD73 in the tumor microenvironment with MEDI9447
- Potent Control of Tumor Growth by CEA/CD3-bispecific Single-chain Antibody Constructs That Are Not Competitively Inhibited by Soluble CEA
- Direct targeting of αvβ3 integrin on tumor cells with a monoclonal antibody, Abegrin™
- Antibody–Drug Conjugates Bearing Pyrrolobenzodiazepine or Tubulysin Payloads Are Immunomodulatory and Synergize with Multiple Immunotherapies
- Intratumoral IL12 mRNA Therapy Promotes TH1 Transformation of the Tumor Microenvironment
- Design and Efficacy of a Monovalent Bispecific PD-1/CTLA4 Antibody That Enhances CTLA4 Blockade on PD-1+ Activated T Cells
- Abstract LB-158: MEDI4736: Delivering effective blockade of immunosupression to enhance tumour rejection: Monoclonal antibody discovery and preclinical development
- CEA/CD3 bispecific antibody MEDI-565/AMG 211 activation of T cells and subsequent killing of human tumors is independent of mutations commonly found in colorectal adenocarcinomas
- Enhanced tumor-targeting selectivity by modulating bispecific antibody binding affinity and format valence
- Synthesis of adenoviral targeting molecules by intein-mediated protein ligation
- Resistance to Durvalumab and Durvalumab plus Tremelimumab Is Associated with Functional STK11 Mutations in Patients with Non–Small Cell Lung Cancer and Is Reversed by STAT3 Knockdown
- Antibody-Dependent Cell-Mediated Cytotoxicity Effector-Enhanced EphA2 Agonist Monoclonal Antibody Demonstrates Potent Activity against Human Tumors
- Targeting Adenoviral Vectors by Using the Extracellular Domain of the Coxsackie-Adenovirus Receptor: Improved Potency via Trimerization
- A Novel Murine GITR Ligand Fusion Protein Induces Antitumor Activity as a Monotherapy That Is Further Enhanced in Combination with an OX40 Agonist
- Distinct mechanisms govern populations of myeloid-derived suppressor cells in chronic viral infection and cancer
- Oncolytic VSV Primes Differential Responses to Immuno-oncology Therapy
- The ATR inhibitor ceralasertib potentiates cancer checkpoint immunotherapy by regulating the tumor microenvironment
- Potent Immune Modulation by MEDI6383, an Engineered Human OX40 Ligand IgG4P Fc Fusion Protein